Читать книгу Clinical Pharmacology and Therapeutics - Группа авторов - Страница 145

In cost–benefit analysis (CBA) both the costs and the outcomes of alternative interventions are expressed in monetary units. This requires a financial value to be attached to the benefit of treatments, often by asking patients or the public to state how much they would be willing to pay for the effects of the intervention. In the CBA, treatments are judged to offer value for money if the cost of the treatment is less than the value placed on the benefits of the treatment. While an approach that has a good basis in economic theory, CBA can be a problematic form of analysis in healthcare because of the difficulties in asking people to place a notional monetary value on health benefits, and is encountered less frequently in pharmacoeconomics literature.